Cervarix™ – a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer

Abstract excerpt

Cervical cancer continues to have a devastating impact on women worldwide. An estimated 470,000 women are diagnosed with the disease every year and, of these, > 230,000 die from it. Recent decades have witnessed considerable advances in our understanding of cervical carcinogenesis, in particular the causal role that oncogenic human papillomavirus infection plays in its etiology. In countries that lack organized...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cervical Cancer and HPV Research
• Share to Hepatitis B Virus Studies
• Share to Immunotherapy and Immune Responses